MedTrace Logo

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

NCT03360708 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-28

No results posted yet for this study

Summary

This pilot early phase I trial studies the side effects of vaccine therapy in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy may work better in treating patients with glioblastoma.

Conditions

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine

Given ID

Sponsors & Collaborators

Principal Investigators

  • Ian Parney · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-27
Primary Completion
2021-06-02
Completion
2021-06-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360708 on ClinicalTrials.gov